肿瘤细胞治疗研究
英文原题：Lymphoma-derived extracellular vesicles inhibit CAR T cell function.
靶向 CD19 的 CAR T 细胞疗法在治疗复发/难治性 B 细胞淋巴瘤中显示出显著疗效。
CD19 靶向 CAR-T 治疗复发/难治性 B 细胞淋巴瘤疗效显著，但仍有部分患者产生治疗耐药。本研究在体外考察淋巴瘤来源细胞外囊泡（EV）对 CD19 靶向 CAR-T 功能的影响。研究显示，淋巴瘤 EV 表达 CD19 和 CD20 等 B 细胞标志物，并可将这些标志物转移至 CAR-T 细胞膜。在共培养实验中，淋巴瘤 EV 抑制 CAR-T 杀伤肿瘤的能力。
CD19-targeting CAR T cell therapy has shown remarkable efficacy in the treatment of relapsed/refractory B cell lymphoma. However, a proportion of patients exhibit resistance to treatment. We investigate the impact of lymphoma-derived Extracellular Vesicles (EV) on CD19-targeting CAR T cell function in vitro . We demonstrate that lymphoma-EV express B cell markers such as CD19 and CD20, which can be transferred to the CAR T cell membrane. In co-culture experiments, lymphoma-EV suppress the tumour-killing capacity of CAR T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
